Ipertrofan

Mepartricin, the active ingredient in Ipertrofan, is a macrolide antibiotic presented as an oral formulation for systemic use. Approved in the European Union, the product targets pathogens implicated in chronic prostatitis, urogenital infections and chronic pelvic pain syndrome, providing clinicians with a targeted antibacterial option.

GNH USA supplies Ipertrofan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company ensures quality manufacturing, regulatory compliance, and reliable logistics for global distribution.

Ipertrofan (mepartricin) is used to treat bacterial infections of the urogenital tract and related chronic conditions.

- Chronic prostatitis: reduces bacterial load and inflammation in the prostate. - Urogenital infections: eradicates susceptible bacteria causing urinary and genital infections. - Chronic pelvic pain syndrome: alleviates symptoms associated with a bacterial component of pelvic pain.

Adverse reactions to Ipertrofan may vary in frequency and severity.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Diarrhea: loose stools occurring during treatment. - Abdominal pain: discomfort or cramps in the abdomen. - Headache: mild to moderate head pain. - Dizziness: sensation of lightheadedness. - Taste disturbance: altered sense of taste.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction with rash, swelling, and breathing difficulty. - Hepatic enzyme elevation: significant increase in liver function tests. - Clostridioides difficile infection: severe colitis presenting with watery diarrhea. - Severe neutropenia: marked reduction in white blood cells increasing infection risk. - Cardiac arrhythmia: irregular heart rhythm in susceptible individuals.

Before prescribing Ipertrofan, clinicians should consider several safety aspects.

- Renal impairment: assess kidney function and monitor if needed. - Hepatic impairment: use with caution and monitor liver enzymes. - Pregnancy: only if benefit outweighs potential risk; data are limited. - Breastfeeding: avoid unless clearly indicated by a physician. - Concomitant macrolides: avoid additive toxicity. - Store at ambient temperature: keep below 25°C, in original packaging, protected from moisture.

Ipertrofan may interact with other medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Other macrolide antibiotics: increased risk of toxicity. - Anticoagulants (e.g., warfarin): potential for enhanced bleeding. - Statins (e.g., simvastatin): heightened risk of myopathy.

Moderate Interactions (Monitor Closely): - Antacids containing aluminum or magnesium: may reduce absorption. - P‑glycoprotein substrates: possible altered plasma levels. - QT‑prolonging agents: monitor cardiac rhythm.